Vir Biotechnology says FDA grants Fast Track to VIR-5500
Vir Biotechnology said the U.S. Food and Drug Administration granted Fast Track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer. The drug is being co-developed with Astellas Pharma through a global collaboration.